3.96

2.82% -0.12

Tango Therapeutics Inc (TNGX)

Overview News Price History Option Chain Financials Why TNGX Down? Discussions Forecast

Tango Therapeutics Inc stock is traded at $3.96, with a volume of 90,716. It is down -2.82% in the last 24 hours and down -44.55% over the past month. Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

Previous Close:

$4.08

Open:

$4.07

24h Volume:

90,716

Relative Volume:

0.05

Market Cap:

$426.45M

Revenue:

$42.51M

Net Income/Loss:

$-116.49M

P/E Ratio:

-3.2727

EPS:

-1.21

Net Cash Flow:

$-120.82M

1W Performance:

+1.15%

1M Performance:

-44.55%

6M Performance:

-46.92%

1Y Performance:

-46.71%

1-Day Range:

$3.92

$4.22

1-Week Range:

$3.54

$4.22

52-Week Range:

$2.70

$13.01

Tango Therapeutics Inc Stock (TNGX) Company Profile

Name

Tango Therapeutics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

(857) 320-4900

Address

201 BROOKLINE AVENUE, BOSTON

Employee

140

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

TNGX's Discussions on Twitter

Compare TNGX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNGX	3.955	426.45M	42.51M	-116.49M	-120.82M	-1.21
VRTX	445.46	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	736.00	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	585.04	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	247.45	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.20	24.49B	3.30B	-501.07M	1.03B	11.54

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-08-23	Initiated	B. Riley Securities	Buy
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-20-21	Initiated	SVB Leerink	Outperform

Tango Therapeutics Inc Stock (TNGX) Latest News

Nov 19, 2024

Tango Therapeutics director Mace Rothenberg acquires $74,000 in stock By Investing.com - Investing.com Canada

Nov 19, 2024

Nov 18, 2024

Tango Therapeutics director Mace Rothenberg acquires $74,000 in stock - Investing.com

Nov 18, 2024

Nov 17, 2024

Trv Gp Iv LLC Cuts Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - MarketBeat

Nov 17, 2024

Nov 15, 2024

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Nov 15, 2024

B. Riley Increases Earnings Estimates for Tango Therapeutics - Defense World

Nov 15, 2024

Nov 14, 2024

B. Riley Forecasts Higher Earnings for Tango Therapeutics - MarketBeat

Nov 14, 2024

B. Riley Cuts Tango Therapeutics (NASDAQ:TNGX) Price Target to $8.00 - Defense World

Nov 14, 2024

Nov 13, 2024

Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 inhibitor progress - Investing.com

Nov 13, 2024

Nov 12, 2024

Tango Therapeutics (NASDAQ:TNGX) Earns “Buy” Rating from HC Wainwright - Defense World

Nov 12, 2024

Nov 11, 2024

The Analyst Landscape: 5 Takes On Tango Therapeutics - Benzinga

Nov 11, 2024

B. Riley Has Lowered Expectations for Tango Therapeutics (NASDAQ:TNGX) Stock Price - MarketBeat

Nov 11, 2024

FY2024 Earnings Forecast for TNGX Issued By Leerink Partnrs - Defense World

Nov 11, 2024

Leerink Partnrs Brokers Increase Earnings Estimates for TNGX - MarketBeat

Nov 11, 2024

Nov 09, 2024

EcoR1 Capital sells $8.4 million in Tango Therapeutics stock - Investing.com India

Nov 09, 2024

EcoR1 Capital sells $8.4 million in Tango Therapeutics stock By Investing.com - Investing.com Australia

Nov 09, 2024

Tango Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 08, 2024

Nov 07, 2024

Tango Therapeutics sees $9.67m stock sale by Boxer Capital - Investing.com India

Nov 07, 2024

Tango Therapeutics (NASDAQ:TNGX) Price Target Lowered to $8.00 at Guggenheim - MarketBeat

Nov 07, 2024

Tango Therapeutics Advances Cancer Treatment Pipeline - TipRanks

Nov 07, 2024

Nov 06, 2024

Two to Tango: Brain cancer drugs go further into development - BioWorld Online

Nov 06, 2024

Tango stock plunges 28% amid pipeline updates, Q3 earnings report (NASDAQ:TNGX) - Seeking Alpha

Nov 06, 2024

U.S. Stock market: Sunnova energy(-42.35%0, Zoomcar(-38.48%), Tango therapeutics(-27.22%) among stock losers during early trading - Business Upturn

Nov 06, 2024

Tango Shares Plunge After 3Q Loss, Product Plans - MarketWatch

Nov 06, 2024

Tango Therapeutics advances cancer drug into full development By Investing.com - Investing.com Canada

Nov 06, 2024